Content Includes:
- Screening for problematic alcohol use and diagnosing Alcohol Use Disorder
- Alcohol withdrawal and its treatment
- Evidence-based psychosocial treatments
- Pharmacotherapies for Alcohol Use Disorder
Presenter
Henry Kranzler, MD
Dr. Kranzler's research focuses on the genetics and pharmacological treatment of substance dependence, with a particular emphasis on precision addiction medicine. His research has been continuously supported since 1987 by grants from the National Institutes of Health. He has authored or co-authored more than 500 journal articles, book chapters, and books, is a member of the editorial board of five peer-review journals, and is the Editor of Alcoholism: Clinical and Experimental Research. His work currently focuses on the molecular genetics of substance dependence and the personalized treatment of alcohol, opioid, and nicotine use disorders using a pharmacogenetic approach.
Henry Kranzler, MD ~ is a member of the Dicerna scientific advisory board and a member of the American Society of Clinical Psychopharmacology's Alcohol Clinical Trials Initiative, which during the past three years was supported by Alkermes, Amygdala Neurosciences, Arbor Pharmaceuticals, Dicerna, Ethypharm, Indivior, Lundbeck, Mitsybishi and Otsuka. Dr. Kranzler is also named as an inventor on PCT patent application #15/878.640 entitled: "Genotype-guided dosing of opioid agonists" filed January 24, 2018.
Learning Outcome(s)
At the conclusion of this learning collaborative, (at least 75% of) participants will be able to identify at least three evidence-based strategies that are designed to enhance the clinical team-based care of patients with substance or opioid use disorders treatment.
Disclosure
The following activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content for this activity have reported the following financial relationship(s)* with ineligible company(ies)**. All of the relevant financial relationships listed for these individuals have been mitigated.
Other planning committee member(s), speaker(s), activity director(s), author(s) or anyone in a position to control the content for this activity report NO financial relationship(s)* with any ineligible company(ies)**.
* A “financial relationship" includes employee, researcher (named as the PI), consultant, advisor, speaker, independent contractor (including contracted research), royalties or patent beneficiary, executive role, and/or an ownership interest (not including stocks owned in a managed portfolio).
** An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Bibliographic Resources
Alcohol Consumption Questions (AUDIT-C): An Effective Brief Screening Test for Problem Drinking. Archives of Internal Medicine. 1998;158(16):1789-1795.
Diagnostic and Statistical Manual of Mental Disorders. 5 ed: American Psychiatric Association; 2013.
Cohen E, Feinn R, Arias A, Kranzler HR. Alcohol treatment utilization: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug and Alcohol Dependence. 2007;86(2):214-221.
Jesse S, Bråthen G, Ferrara M, et al. Alcohol withdrawal syndrome: mechanisms, manifestations, and management. Acta Neurol Scand. 2017;135(1):4-16.
Ahmed S, Stanciu CN., Kotapati, PV., Ahmed, R., Bhivandkar, S., Khan, AM., Afrid, A., Qureshi, M., Esang, M.,. Effectiveness of Gabapentin in Reducing Cravings and Withdrawal in Alcohol Use Disorder: A Meta-Analytic Review. The Primary Care Companion for CNS Disorders. 2019.
Fuller RK, Branchey L, Brightwell DR, et al. Disulfiram Treatment of Alcoholism: A Veterans Administration Cooperative Study. JAMA. 1986;256(11):1449-1455.
Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the Treatment of Alcohol Dependence. Archives of General Psychiatry. 1992;49(11):876-880.
Soyka M, Rösner S. Emerging drugs to treat alcoholism. Expert Opinion on Emerging Drugs. 2010;15(4):695-711.
Garbutt JC, Kranzler HR, O’Malley SS, et al. Efficacy and Tolerability of Long-Acting Injectable Naltrexone for Alcohol Dependence A Randomized Controlled Trial. JAMA. 2005;293(13):1617-1625.
Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. The Lancet. 2011;377(9776):1506-1513.
Maria A. Sullivan, M.D. , Ph.D. ,, Adam Bisaga, M.D. ,, Martina Pavlicova, Ph.D. ,, et al. A Randomized Trial Comparing Extended-Release Injectable Suspension and Oral Naltrexone, Both Combined With Behavioral Therapy, for the Treatment of Opioid Use Disorder. American Journal of Psychiatry. 2019;176(2):129-137.
Sass H, Soyka M, Mann K, Zieglgänsberger W. Relapse Prevention by Acamprosate: Results From a Placebo-Controlled Study on Alcohol Dependence. Archives of General Psychiatry. 1996;53(8):673-680.
1Blodgett JC, Del Re AC, Maisel NC, Finney JW. A Meta-Analysis of Topiramate's Effects for Individuals with Alcohol Use Disorders. Alcoholism: Clinical and Experimental Research. 2014;38(6):1481-1488.
